CABA
USDCabaletta Bio Inc. Common Stock
Reaalajas hind
Hinnagraafik
Põhinäitajad
Turunäitajad
Avatud
$2.860
Kõrge
$2.970
Madal
$2.630
Maht
3.67M
Ettevõtte fundamentaalnäitajad
Turukapitalisatsioon
247.0M
Tööstusharu
Biotehnoloogia
Riik
United States
Kauplemisstatistika
Keskmine maht
3.63M
Börs
NMS
Valuuta
USD
52 nädala vahemik
Seotud uudised
Cabaletta Bio Reports Third Quarter 2025 Financial Results and Provides Business Update
Rese-cel data presented at multiple medical meetings demonstrated potentially transformative, drug-free clinical responses with a favorable safety profile for autoimmune patients supporting outpatient use All myositis
FDA's Rigid Approach Adds Uncertainty To uniQure's Accelerated Pathway For Huntington's Gene Therapy
William Blair notes FDA's tougher stance on gene therapy programs as AMT-130 faces uncertainty in its accelerated approval timeline.
Cantor Fitzgerald Maintains Overweight on Cabaletta Bio, Raises Price Target to $30
Cantor Fitzgerald analyst Josh Schimmer maintains Cabaletta Bio with a Overweight and raises the price target from $15 to $30.
Cabaletta Bio Presents Positive Clinical Data and Development Updates for Rese-cel at ACR Convergence 2025
– All myositis patients in the Phase 1/2 DM/ASyS cohort with sufficient follow-up who met key registrational inclusion criteria exceeded the registrational primary endpoint, demonstrating major TIS responses with no
Seotud aktsiad
Püsi kursis
Määrake hinnateavitused, hankige tehisintellekti analüüsi uuendusi ja reaalajas turuuudiseid.